Global Allogeneic Stem Cell Transplantation Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Allogeneic Stem Cell Transplantation Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Allogeneic Stem Cell Transplantation report published by MRAResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Allogeneic Stem Cell Transplantation market is projected to reach US$ 1503.6 million in 2033, increasing from US$ 1000 million in 2022, with the CAGR of 6.0% during the period of 2023 to 2033. Demand from Hospital and Ambulatory Surgical Center are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Allogeneic Stem Cell Transplantation industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2023 to 2033.
Globally, Allogeneic Stem Cell Transplantation key companies include Mesoblast Limited, Gamida Cell Ltd., Novartis International AG, Cellectis SA, Magenta Therapeutics Inc., Fate Therapeutics Inc., Cynata Therapeutics Limited, Kiadis Pharma N.V and Takeda Pharmaceutical Company Limited, etc. Mesoblast Limited, Gamida Cell Ltd., Novartis International AG are top 3 players and held % share in total in 2022.
Allogeneic Stem Cell Transplantation can be divided into Unmodified Stem Cell Transplant, T-cell Depleted Transplant, Cord Blood Transplant and Donor Lymphocyte Infusion, etc. Unmodified Stem Cell Transplant is the mainstream product in the market, accounting for % share globally in 2022.
Allogeneic Stem Cell Transplantation is widely used in various fields, such as Hospital, Ambulatory Surgical Center and Others,, etc. Hospital provides greatest supports to the Allogeneic Stem Cell Transplantation industry development. In 2022, global % share of Allogeneic Stem Cell Transplantation went into Hospital filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Allogeneic Stem Cell Transplantation market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
Mesoblast Limited
Gamida Cell Ltd.
Novartis International AG
Cellectis SA
Magenta Therapeutics Inc.
Fate Therapeutics Inc.
Cynata Therapeutics Limited
Kiadis Pharma N.V
Takeda Pharmaceutical Company Limited
JCR Pharmaceuticals Co., Ltd.
Pluristem Therapeutics Inc.
Celularity Inc.
Lineage Cell Therapeutics Inc.
Nohla Therapeutics Inc.
Orchard Therapeutics Plc
Segment by Type
Unmodified Stem Cell Transplant
T-cell Depleted Transplant
Cord Blood Transplant
Donor Lymphocyte Infusion
Hospital
Ambulatory Surgical Center
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Allogeneic Stem Cell Transplantation market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2033).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Allogeneic Stem Cell Transplantation introduction, etc. Allogeneic Stem Cell Transplantation Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12MRAResearch’s Conclusions of Allogeneic Stem Cell Transplantation market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by MRAResearch.
North America, Europe and Asia Pacific are the key regions for Allogeneic Stem Cell Transplantation industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2023 to 2033.
Globally, Allogeneic Stem Cell Transplantation key companies include Mesoblast Limited, Gamida Cell Ltd., Novartis International AG, Cellectis SA, Magenta Therapeutics Inc., Fate Therapeutics Inc., Cynata Therapeutics Limited, Kiadis Pharma N.V and Takeda Pharmaceutical Company Limited, etc. Mesoblast Limited, Gamida Cell Ltd., Novartis International AG are top 3 players and held % share in total in 2022.
Allogeneic Stem Cell Transplantation can be divided into Unmodified Stem Cell Transplant, T-cell Depleted Transplant, Cord Blood Transplant and Donor Lymphocyte Infusion, etc. Unmodified Stem Cell Transplant is the mainstream product in the market, accounting for % share globally in 2022.
Allogeneic Stem Cell Transplantation is widely used in various fields, such as Hospital, Ambulatory Surgical Center and Others,, etc. Hospital provides greatest supports to the Allogeneic Stem Cell Transplantation industry development. In 2022, global % share of Allogeneic Stem Cell Transplantation went into Hospital filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Allogeneic Stem Cell Transplantation market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
Mesoblast Limited
Gamida Cell Ltd.
Novartis International AG
Cellectis SA
Magenta Therapeutics Inc.
Fate Therapeutics Inc.
Cynata Therapeutics Limited
Kiadis Pharma N.V
Takeda Pharmaceutical Company Limited
JCR Pharmaceuticals Co., Ltd.
Pluristem Therapeutics Inc.
Celularity Inc.
Lineage Cell Therapeutics Inc.
Nohla Therapeutics Inc.
Orchard Therapeutics Plc
Segment by Type
Unmodified Stem Cell Transplant
T-cell Depleted Transplant
Cord Blood Transplant
Donor Lymphocyte Infusion
Segment by Application
Hospital
Ambulatory Surgical Center
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Allogeneic Stem Cell Transplantation market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2033).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Allogeneic Stem Cell Transplantation introduction, etc. Allogeneic Stem Cell Transplantation Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12MRAResearch’s Conclusions of Allogeneic Stem Cell Transplantation market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by MRAResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices